Physician profile
Siva Maran
NPI 1619965043
$2,448.42
in general payments reported to CMS, 2019-2025
22 companies · $368 in 2025
The $368 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $356 · 2021: $468 · 2022: $383 · 2023: $249 · 2024: $383 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $615.52 | 2020-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.89 | 2019-2023 | Xifaxan |
| Abbvie INC. | $346.41 | 2019-2025 | |
| Gilead Sciences, INC. | $276.85 | 2020-2025 | Epclusa |
| Celgene Corporation | $108.67 | 2021-2024 | Zeposia |
| Pfizer INC. | $90.71 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.67 | 2019-2024 | Entyvio |
| Ardelyx, INC. | $55.30 | 2024-2025 | Ibsrela |
| Neurelis, INC. | $45.26 | 2021 | |
| Janssen Pharmaceuticals, INC | $39.65 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $27.63 | 2022 | |
| Lucid Diagnostics INC. | $26.95 | 2025 | |
| Redhill Biopharma INC. | $24.12 | 2020-2021 | |
| Madrigal Pharmaceuticals | $23.70 | 2025 | Rezdiffra |
| Allergan, INC. | $23.66 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $21.62 | 2024 | Hyrimoz |
| Lilly USA, LLC | $20.39 | 2025 | Omvoh |
| Teva Pharmaceuticals USA, INC. | $18.21 | 2022 | |
| Amgen INC. | $16.30 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.03 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $13.78 | 2023 | Sutab |
| Biohaven Pharmaceuticals, INC. | $11.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Siva Maran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.